Leucid Bio provides business update and outlook for 2023

Proprietary Lateral CAR Platform achieved pre-clinical proof-of-concept data demonstrating prolonged disease-free survival compared to other CAR T-cell products.Lead programme, LEU011 has completed

Related Keywords

United States ,United Kingdom ,London ,City Of ,Eastbourne ,East Sussex ,America ,Ian Miscampbell ,Dennis Riedl ,Prnewswire Leucid Bio ,Mark Docherty ,Arindam Mitra ,Belinda Carlsen ,Marc Davies ,John Maher ,Leucid Bio ,Senior Leadership Team ,King College London ,Seasoned Life Sciences ,Royal College Of Pathologists ,Management Team Artin Moussavi ,Clinical Development ,Dr John Maher At King College London ,Proprietary Lateral ,Senior Leadership ,Executive Team ,Innovative Licensing ,Access Pathway ,Chimeric Antigen Receptort Cell ,Chief Scientific Officer ,College London ,Clean Room ,Chief Executive Officer ,Artin Moussavi ,Chief Financial Officer ,Chief Operating Officer ,Life Sciences ,North America ,Chief Business Officer ,Executive Chairman Ian Miscampbell ,Interim Executive Chairman ,Clinical Trial Application ,Scientific Founder ,Michel Sadelain ,Memorial Sloan Kettering Cancer Center ,Chief Investigator ,Royal College ,General Medical Council ,Consultant Immunologist ,Seleucid ,Rovides ,Business ,Update ,Outlook ,023 ,